Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD4205 with Itraconazole or Carbamazepine in Healthy Adults
NCT05486949Phase 1Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of golidocitinib in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Maximum plasma concentration up to 18 days, Time to reach maximum plasma concentration up to 18 days and 2 more. Started Jul 2022; status: completed.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05486949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05486949.